Andrew C. Jackson - 03 Jun 2022 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role
Chief Financial Officer
Signature
/s/ Andrew C. Jackson
Issuer symbol
ERNA
Transactions as of
03 Jun 2022
Net transactions value
$0
Form type
4
Filing time
06 Jun 2022, 17:01:15 UTC
Previous filing
01 Jun 2022
Next filing
02 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERNA Stock Option (right to buy) Award $0 +664,800 $0.000000 664,800 03 Jun 2022 Common Stock, par value $0.005 per share 664,800 $0.6086 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable over four years (subject to continued service), with 25% of the shares vesting on May 31, 2023 and the remaining shares vesting in 36 substantially equal monthly installments thereafter.